Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2013

View Archived Issues

A proof of principle study of a predictive biomarker-based blood test for suicide risk

Preclinical validation of a first-in-class p53 pathway reactivator for the treatment of cancer

Demonstration of an effective cure for symptomatic Ebola virus infection

Lumena begins patient recruitment for CLARITY and IMAGO

New FSH-R agonists discovered by Merck KGaA

Novel TLR7/TLR8 receptor agonists disclosed by Janssen R&D Ireland

Researchers at Lupin synthesize new agents for HCV infection

Chinese researchers prepare novel tyrosine-protein kinase inhibitors

New P2X receptor antagonists described by Shionogi & Co.

New adenoviral vector with enhanced immunogenicity against HCV

ReNeuron's retinal stem cell therapy receives orphan drug status

Sanofi Pasteur reports topline data for Fluzone High-Dose vaccine

CP-9531 shows promising efficacy and safety in vivo

KemPharm reports data from KP-201 study

Alcobra enrolls first patient in predominantly inattentive ADHD study

Ultragenyx Pharmaceutical's triheptanoin IND is now active

Oragenics reports data from lantibiotics program

Japan's MHLW Drug Committee endorses QVA-149 approval

FDA approves first topical therapy for erythema in patients with rosacea

Takeda and Zinfandel begin phase III trial to delay MCI in Alzheimer's disease

Rigel to discontinue R-343 development

FDA grants priority review to Nexavar sNDA in RAI-refractory differentiated thyroid cancer

Sangamo BioSciences signs definitive agreement to acquire Ceregene

Lipidor's phase I/II trial of Akvano/calcipotriol spray meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...